Emergent BioSolutions Inc.
EBS· NYSE
EBSEmergent BioSolutions Inc.
Filed Mar 4, 2025 · 10-K · 63 days after period end · 0001367644-25-000021
derived · Computed from the longer spans the company filed.
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022 | Q4 2021 |
|---|---|---|---|---|
| Revenue | $194.70M | $276.60M | $330.20M | $732.90M |
| Net Income | -$31.30M | -$49.50M | -$67.00M | $193.10M |
| EPS Diluted | — | — | -$1.34 | $3.60 |
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2024 · filed Mar 4, 2025 · 63 d after period end
